PROGRESS: Acceptability of depo-subQ in Uniject
FHI 360's PROGRESS project worked with ministries of health and local partners in Senegal and Uganda to conduct an acceptability study of the subcutaneous delivery of injectable contraceptives with the Uniject™ device. The new subcutaneous product, called Sayana® Press, had originally been known as depo-subQ provera 104™ in Uniject. The study assessed acceptability among family planning clients and providers, including community health workers, and offered recommendations for the introduction of this method. Results of the study are summarized in this brief [PDF, 665 KB].
Researchers anticipate that Sayana Press will improve access to family planning services by providing an affordable and safe contraceptive option through community-based providers in remote areas. Pfizer developed depo-subQ, a subcutaneously injected formulation of the drug depot-medroxyprogesterone acetate (DMPA or the brand name Depo-Provera®). The collaborative efforts of PATH, Becton Dickenson and Pfizer make this DMPA formulation available in Uniject — a prefilled, autodisable injection system that is appropriate for low-resource settings.
PROGRESS (Program Research for Strengthening Services) was a five-year project awarded to FHI 360 by the U.S. Agency for International Development (USAID) in June 2008. The project sought to improve access to family planning among underserved populations by providing global technical leadership and working in selected countries.